Drugs / Mesothelin-directed CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03747965 | Nov 2018 → Nov 2019 | cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesothelin-directed CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03747965 ↗ |
| Action | Inhibit | “use the technique of CRISPR-Cas9 to knocked out the PD-1 of the chimeric antigen receptor (CAR) T cells” NCT03747965 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) T cells” NCT03747965 ↗ |